GO-DS21

GO-DS21 is a fundamental, preclinical, and clinical innovative research program that will maximize the use of existing clinical registries and cohorts in addition to generating new data. These data will comprise the so-called Don Syndrome (DS) comorbidities network, including data from registries and cohorts in the UK (Clinical Practice Research Datalink (CPRD) with at least 6,000 reported DS cases), France, Spain and Europe (three major European clinics specializing in DS). We will explore how intrinsic (genetic and pathway-driven) and extrinsic (environmental and epigenetic) factors can lead to such comorbid states. The innovative approach to be used in this project will help improve early diagnosis, prognosis and treatment of DS related comorbidities, whilst establishing novel recommendations and targeted interventions to prevent or at least minimize the appearance of obesity within the context of ID in people with DS. Beyond the impact on individuals with DS, we expect that our gained knowledge will also help other ID patients, as well as individuals in the general population in better coping with obesity and cognitive impairment. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 848077. This website reflects only the view of the authors and the European Commission is not responsible for any use that may be made of the information it contains.